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ABSTRACT 
Background: Little is known about enzymatic N-glycosylation in type 2 diabetes, a common 
posttranslational modification of proteins influencing their function and integrating genetic and 
environmental influences. We sought to gain insights into N-glycosylation to uncover yet 
unexplored pathophysiological mechanisms in type 2 diabetes.  
Methods: Using a high-throughput MALDI-TOF mass spectrometry method, we measured 
N-glycans in plasma samples of the DiaGene case-control study (1583 cases and 728 controls). 
Associations were investigated with logistic regression and adjusted for age, sex, body mass index, 
high-density lipoprotein-cholesterol, non-high-density lipoprotein-cholesterol, and smoking. 
Findings were replicated in a nested replication cohort of 232 cases and 108 controls.  
Results: Eighteen glycosylation features were significantly associated with type 2 diabetes. 
Fucosylation and bisection of diantennary glycans were decreased in diabetes (odds ratio (OR) = 
0.81, p = 1.26E-03, and OR = 0.87, p = 2.84E-02, respectively), whereas total and, specifically, 
alpha2,6-linked sialylation were increased (OR = 1.38, p = 9.92E-07, and OR= 1.40, p= 5.48E-
07). Alpha2,3-linked sialylation of triantennary glycans was decreased (OR = 0.60, p = 6.38E-11).  
Conclusions: While some glycosylation changes were reflective of inflammation, such as 
increased alpha2,6-linked sialylation, our finding of decreased alpha2,3-linked sialylation in type 
2 diabetes patients is contradictory to reports on acute and chronic inflammation. Thus, it might 
have previously unreported immunological implications in type 2 diabetes.  
General significance: This study provides new insights into N-glycosylation patterns in type 
2 diabetes, which can fuel studies on causal mechanisms and consequences of this complex 
disease.  
Keywords: diabetes complications, diabetes mellitus, inflammation; MALDI-TOF-MS; N-
glycosylation; sialic acid 
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1 INTRODUCTION 
Diabetes mellitus type 2 is a disease with enormous morbidity and excess mortality [1]. Intensive 
therapy can reduce the burden of complications of the disease, but only to about 50% [2]. It is 
well-recognized as a multifactorial disease in which genetic susceptibility, numerous metabolic 
pathways, lifestyle and environmental factors interact at multiple levels [3]. These factors are 
known to also influence protein N-glycosylation [4-6]. Glycomics is a relatively new ‘omics’ 
approach that analyses complex sugar structures (glycans), which are among the four principal cell 
components besides DNA, proteins, and lipids [4]. Pathophysiological processes in type 2 diabetes 
are intricate and incompletely understood. ‘Omics’ approaches may increase our understanding of 
the pathophysiology and eventually advance the development of personalized diabetes medicine, 
early detection, and more effective treatment approaches [7].  
Little is known about the enzymatic process called N-glycosylation in type 2 diabetes. N-
Glycosylation is a common posttranslational modification of proteins involving the action of 
hundreds of different proteins such as glycosyltransferases, glycosidases, and transporters [4, 8]. 
Carbohydrate metabolic pathways are directly related to the biosynthesis of monosaccharides that 
are the substrates for glycosylation [6]. N-Glycans are highly diverse and have multiple functions, 
including important roles in protein folding, stability, and receptor-ligand interaction [4, 8]. N-
Glycosylation is not to be confused with non-enzymatic glycation, such as in glycated hemoglobin 
(HbA1c) and in advanced glycation end products, which has been extensively investigated and is 
well-known for its detrimental effects on plasma proteins and DNA [9].  
Most of the major plasma proteins are glycosylated and N-glycans have already been 
proposed as biomarkers and therapeutic targets for various inflammatory diseases and cancer [4]. 
In healthy individuals, plasma protein glycosylation is constant over time, but can dramatically 
change because of a pathological condition, especially upon inflammation [10, 11]. Furthermore, 
N-glycosylation changes have been associated with obesity, smoking, and aging [12-15], which 
are recognized risk factors for type 2 diabetes. However, a limited number of reports exist on 
plasma N-glycosylation in diabetes. Fucosylation of plasma N-glycans is partly regulated by 
hepatocyte nuclear factor 1-α (HNF1A) [16], of which rare variants cause type 3 maturity-onset 
diabetes of the young (MODY) [17] and of which a common genetic variant has been linked to 
type 2 diabetes [18]. Recently, we found decreased galactosylation and sialylation and increased 
bisection of fucosylated structures on immunoglobulin (Ig)G in type 2 diabetes, which corresponds 
with an increased inflammatory potential of IgG [19]. Reduced IgG sialylation in mice was shown 
to be implicated in obesity-induced insulin resistance [20]. In total plasma N-glycome, Testa et al. 
found that monogalactosylated, core-fucosylated diantennary N-glycans were reduced in 
individuals with type 2 diabetes compared to controls [21]. In this promising pioneering work, a 
limited number of glycan structures were detected after the removal of sialic acids. Sialylation, 
however, has a crucial role in the functionality of N-glycans [22], and total plasma levels of sialic 
acid have been associated with incident type 2 diabetes [23, 24]. Recently, associations of 
increased complexity and sialylation of plasma N-glycan structures with a higher risk of type 2 
diabetes were reported [25]. Therefore, comprehensive research of the total plasma N-glycome, 
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including detailed sialylation analyses, is indicated to understand the contribution of these 
multifaceted structural glycan features to this complex disease. Our MALDI-TOF MS-based high-
throughput approach is well suited for this purpose, as it identifies 70 glycan compositions and 
reveals information on not only fucosylation, bisection and sialylation [26], but also on sialic-acid 
linkage variants that have not been previously investigated. 
In the present study, we sought to reveal differences in the detailed structural features of 
the plasma N-glycome between type 2 diabetes patients and healthy controls in a large case-control 
study, and performed a nested replication in a subsample of the population to gain a first insight 
into the possible involvement of plasma protein N-glycans in the pathophysiology of type 2 
diabetes.  
2 MATERIAL AND METHODS 
2.1 Subjects 
Plasma samples from the DiaGene study were used for the N-glycan measurements. DiaGene is a 
case-control study on type 2 diabetes (1886 cases and 854 controls) collected from the Eindhoven 
area in the Netherlands and is described in detail elsewhere [27], with basic characteristics 
summarized in Table 1. All samples were collected and stored according to the same protocol as 
described previously. The control samples were collected, stored and processed on the same 
location as the primary care patient samples. 
All participants have given written informed consent. The study was approved by the Medical 
Ethical Committee of the Erasmus MC and is in compliance with the Declaration of Helsinki 
principles. 
2.2 Total plasma N-glycome analysis and MS data processing 
N-Glycans were analyzed after sialic-acid derivatization by a previously established 
MALDI-TOF MS method [26, 28], with minor modifications. Briefly, 5 μL plasma sample was 
denatured by the addition of 10 μL of 2% sodium dodecyl sulfate and incubation for 10 min at 60 
°C. For glycan release, 10 μL of 2.5× phosphate-buffered saline containing 2% nonidet P-40 and 
0.5 mU peptide-N-glycosidase F (Roche Diagnostics, Mannheim, Germany) were added followed 
by incubation for 16 h at 37 °C. Thereafter, during the derivatization procedure, α2,6-linked sialic 
acids were ethyl-esterified and α2,3-linked sialic acids were lactonized, facilitating mass-based 
discrimination of sialic-acid linkage variants. Released glycans were purified using a 96-well filter 
plate with a GHP membrane (AcroPrep Advance 96 Filter plate, Pall Corporation, Ann Arbor, MI) 
on a Hamilton liquid-handling system. The derivatized sialylated glycans were detected 
simultaneously with nonsialylated N-glycans in positive-ion reflectron mode. In short, 10 μL of 
sample was premixed with 10 μL of 5 mg/mL super-DHB (Sigma-Aldrich, Steinheim, Germany) 
in 99% acetonitrile with 1 mM NaOH in a 384-well plate, 2 μL of which was spotted on plate. 
Mass spectra were acquired by an ultrafleXtreme MALDI-TOF mass spectrometer equipped with 
a Smartbeam-II laser operated by flexControl 3.4 (Build 135) (Bruker Daltonics, Bremen, 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   5 
Elsevier B.V. All rights reserved 
Germany). A total of 20,000 shots at 1,000 Hz were accumulated per spectrum with a mass range 
of m/z 1,000–5,000. The MALDI-TOF-MS was calibrated using the Bruker Peptide Calibration 
Standard II. An acceleration voltage of 25 kV was applied following a 140 ns extraction delay. 
Using flexAnalysis 3.4 (Build 76) Batch Process, raw data were baseline-subtracted (TopHat) and 
smoothed (SavitzkyGolay), and .xy files were generated for further processing.  
Table 1. Characteristics of the study populations.  
 Discovery cohort Replication cohort 
 Cases Controls Cases Controls 
Total number 1583 728 232 108 
Age (years) 65.2 ± 10.9 65.8 ± 7.0 65.1 ± 7.8 65.8 ± 5.0 
Sex (female) (n, %) 748 (47.3) 456 (62.6)c 90 (38.8) 42 (38.9) 
BMI (kg/m2) 29.4 (26.6-33.0) 25.4 (23.3-27.8)c 30 (27.4-34) 25.8 (23.7-27.9)c 
HDL-c (mmol/l) 1.10 (0.94-1.30) 1.42 (1.22-1.67)c 1.18 (1.00-1.40) 1.39 (1.19-1.64)c 
Non-HDL-c (mmol/l)  3.00 (2.50-3.68) 4.03 (3.43-4.76)c 2.85 (2.4-3.46) 4.19 (3.54-4.66)c 
Creatinine (μmol/l) 77 (67-92) 71 (63-80)c 77 (66-91) 77 (67-86) 
Ever smoked (n, %) 1079 (74.3) 480 (68.4)b 158 (75.2) 64 (61.0)a 
Currently smoking (n, %) 260 (18.1) 80 (11.4)c 34 (16.3) 9 (8.6) 
Systolic BP (mmHg)  142 ± 19 139 ± 20b 142 ± 19 139 ± 18 
Cardiovascular disease (n, %) 539 (37.1) 66 (9.4)c 89 (41.2) 0c 
HbA1c (mmol/mol)  50.8 (45.4-59.6) 37.7 (35.5-38.8)c 51.9 (45.4-60.7) 36.6 (35.5-38.8)c 
Duration of diabetes (years) 8 (3-14) NA 10 (5-16) NA 
Insulin use (n, %) 452 (30.3) NA 89 (40.1) NA 
Diabetic retinopathy (n, %) 223 (15.0) NA 68 (29.4) NA 
Diabetic nephropathy (n, %) 311 (22.2) NA 56 (25.7) NA 
Continuous data are represented as median and interquartile range or as mean ± SD in case of age and systolic blood 
pressure (BP). Clinical variables were compared between cases and controls with the Student’s t-test or the Wilcoxon 
rank-sum test for normal and non-normal distributions, respectively, and with the χ2-test for binary data. All p-values 
are shown for cases vs. controls within the same cohort: a p < 0.05; b p < 0.01; c p < 0.001. BMI, body mass index; BP, 
blood pressure; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; NA = not applicable. 
 
For the analyte composition list, three sum spectra were generated from selected mass 
spectra from cases with and cases without diabetic complications, and healthy controls, eight mass 
spectra per group. In addition to the manual inspection of the peaks in the sum spectra, potential 
modifications for the 20 most abundant glycan compositions, including fragments, potassium 
adducts, and adducts from the derivatization reaction were considered, resulting in a list of 159 
potential analytes with a distinct m/z value (Supplementary Table S1). Our in-house built software 
MassyTools version 0.1.8.1.2 [29] was used for area integration and internal calibration, with a 
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list of high-intensity glycan signals distributed across the detected m/z range applied as calibrants: 
H3N4F1, H4N4F1, H5N4F1, H5N4E1F1, H6N5L1E2, H6N5L1E2F1 (Supplementary Table S1). 
The relative areas of the detected glycans were extracted by summing the isotopes within 80% of 
the isotopic envelope for each species. Furthermore, different quality parameters (see below) were 
calculated using MassyTools. Resulting mass errors and relative standard deviations (SD) of the 
calculated relative intensities of the glycan compositions are presented in Supplementary Table 
S1. For example, the relative SD of the main peak at m/z 2301 was 6.42%. 
Mass spectra were excluded from further analysis if their total intensity was lower than 
50,000 and their “Fraction of analyte area - background area above signal-to-noise ratio” was lower 
than 0.89 (corresponding to the mean minus 4-times the SD to ensure a sufficient intensity for the 
overall profile including minor peaks; see [29] for further details on the quality parameters). The 
reasoning for setting the cut-offs was confirmed by a manual inspection of several borderline 
spectra. After the removal of low-quality spectra, analyte compositions were removed from further 
analysis based on cut-offs for their signal-to-noise ratio, mass accuracy, isotopic pattern quality, 
and presence in a minimum percentage of the spectra within cases, healthy controls, or VisuCon-
F plasma standard samples (Stago BNL, Netherlands). The cut-off values were as follows: signal-
to-noise > 6, ppm error < 20, deviation from the theoretical isotopic pattern < 20 %, and present 
in at least 10% of spectra per group, i.e. cases, controls, or plasma standards. Only non-modified 
glycan compositions were further processed. The sum of the signal intensities of these remaining 
70 compositions was normalized to 1, with each individual composition expressing a fraction 
thereof (total area normalization; see Figure 1 and Supplementary Table S1). From the 70 direct 
traits, 91 derived traits were calculated on the basis of their structural features (Supplementary 
Table S2) [25, 26, 30]. In case of ambiguity due to isomerism, for example in H5N5E1F1, bisection 
of diantennary glycans was assumed rather than an agalactosylated third antenna. 
2.3 Experimental design and statistical analysis 
In total, 2718 samples from the DiaGene cohort, 31 blanks and 155 VisuCon-F standard 
plasma samples were randomized over 31 96-well plates and prepared and analyzed as described 
above. After the removal of low-quality spectra during quality control and samples with 
insufficient clinical information, the discovery cohort data consisted of 1583 cases and 728 
controls. For the nested replication cohort, 232 cases were randomly selected using IBM SPSS 
Statistics (version 21.0) and 108 controls were selected matching on average age and sex 
frequencies as a group. A power calculation was performed using G*Power 3.1 [31]. At alpha = 
0.05, we had 80% power to find odds ratios (ORs) <0.88 or >1.13 in the discovery cohort. 
Statistical analyses were performed in RStudio (version 1.0.136). The distribution of the 
clinical variables was considered normal when Skewness and Kurtosis were within the range of -
1 to +1. Clinical variables were compared between cases and controls with the Student’s t-test or 
the Wilcoxon rank-sum test for normal and non-normal distributions, respectively. Binary data 
were compared with the χ2-test. 
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Direct and derived glycan traits were adjusted for batch effects by preparation day, MALDI 
plate, row and column effect using ComBat package in R. For the analyses of associations of N-
glycans with clinical variables and diabetes, N-glycan relative intensities were centered by 
subtracting the mean and scaled by dividing by the SD. Linear regression was used for associations 
of N-glycans with continuous clinical variables, and logistic regression for associations with sex 
and smoking. Age, sex, and their interaction were used as covariates in a second model for the 
analysis of associations between N-glycans and clinical variables. For the sake of power, we chose 
to analyze the associations between N-glycans and clinical parameters in the entire cohort instead 
of stratifying for case/control status.  
 
Figure 1: A typical MALDI-TOF mass spectrum of plasma protein N-glycans from the DiaGene 
cohort. After enzymatic release of glycans, sialic acids were stabilized in linkage-specific manner and 
analyzed by positive-ion reflectron mode MALDI-TOF-MS. Observed m/z values for [M+Na]+ species 
are depicted, with structures proposed for the most abundant species. The red asterisk marks a fragment of 
the species detected at m/z 2301.840. For the complete list of, in total, 70 quantified glycan species, see 
Supplementary Table S1. The inset shows the enlarged mass window of m/z 3130-3800. 
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Associations of N-glycans with type 2 diabetes were assessed with logistic regression. The 
following covariates were included in three models: 1) age, sex, and their interaction; 2) model 1 
+ body mass index (BMI); and 3) model 2 + high-density lipoprotein-cholesterol (HDL-c), non-
HDL-c, smoking. Outcomes of model 1 reflect the broad differences between cases and controls, 
while model 2 and 3 more specifically reflect the differences that are not mediated through risk 
factors for type 2 diabetes. The age-sex interaction was included as a covariate, since it was 
previously reported to affect various glycan traits [15]. Non-HDL-c was calculated as total 
cholesterol minus HDL-c. Smoking was divided in current smokers vs. former and non-smokers 
(‘Current smoking’) and in current and former smokers (‘Ever having smoked’) vs. non-smokers. 
Whenever values were missing per clinical variable in models 2 and 3, cases were excluded in the 
respective statistical analysis using the complete.cases() function in R; the exact numbers of cases 
and controls per analysis are stated in Table 2. Glycomic data was complete in all cases used for 
statistical analysis. Calculated ORs refer to an increase of one SD in the tested glycan traits. The 
Benjamini-Hochberg procedure [32] was applied to control for multiple testing, using a cutoff of 
q = 0.05 (5% false discovery rate).  
3 RESULTS 
3.1 Data reliability 
The complete list of the 70 quantified glycan compositions as well as additional signals 
from possible modifications and signals that did not pass our quality criteria is given in 
Supplementary Table S1. For the quantified species, relative intensities with their relative SD as 
extracted from technical replicates of 149 plasma standard samples that were randomized and 
measured together with the cohort samples demonstrate overall method repeatability on the direct-
trait level. In addition, Supplementary Table S2 contains relative SD values based on our 91 
derived glycan traits which were calculated from the 70 direct traits. As described before, derived 
glycan traits appear to have a higher technical robustness in glycomics studies compared to directly 
detected compositions [28]. Moreover, derived traits represent the different structural features 
corresponding to biosynthetic pathways in protein glycosylation as known from literature [25, 26, 
30]. 
3.2 Subject characteristics 
Detailed characteristics and numbers of the individuals included and excluded from the 
study are described elsewhere [27]. Details of the cohorts analyzed here for their glycomic 
signatures are given in Table 1 and glycomics data are shown in Figure 1 and Table S3. In both 
cohorts, cases had a higher BMI than controls, and a lower HDL-c and non-HDL-c. Moreover, a 
higher proportion of cases were smokers and had cardiovascular disease (Table 1). Additionally, 
in the discovery cohort, controls were more often female (62.6% vs. 47.3%) and had lower serum 
creatinine than cases. 
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3.3 Association of glycans with age, sex, and risk factors for type 2 diabetes 
The largest effects associated with increasing age were found for decreased galactosylation 
and increased bisection of diantennary glycans (Supplementary Figure S2A and Table S4). With 
increasing age, both α2,3-linked and α2,6-linked sialylation increased for fucosylated glycans, but 
decreased for non-fucosylated glycans. Different glycosylation features showed strong 
associations with sex, and moreover, an interaction between age and sex was observed 
(Supplementary Table S4 and Figure S1).  
After adjustment for the covariates age, sex, and their interaction, multiple associations 
remained significant between glycans and BMI, HDL-c, non-HDL-c, and smoking (excerpt in 
Figure 2 and full version in Supplementary Figure S2B). For BMI, the strongest associations were 
with sialylation and sialic-acid linkage. With increasing BMI, overall sialylation increased in 
diantennary glycans (A2S) and decreased in tetraantennary glycans (A4S). Moreover, higher BMI 
was associated with lower α2,3-linked (A3L) and higher α2,6-linked sialylation (A2E). In addition, 
antennary fucosylation and bisection of several nonsialylated traits were positively associated with 
BMI, whereas bisection of mainly sialylated species and galactosylation of nonsialylated species 
were inversely associated. Smoking showed an association pattern similar to BMI, but additionally 
showed strong associations with fucosylation. For a few traits, sialic-acid linkage was associated 
with BMI and smoking in opposite directions, e.g. in A4F0E and A2(G)L. (Treated) HDL-c and 
non-HDL-c levels were similarly associated with N-glycans, but in the opposite direction from 
BMI and smoking, particularly regarding sialic-acid linkages. HDL-c and non-HDL-c were 
associated with low-complexity glycan traits (MM, MHy) in opposite directions (Supplementary 
Figure S2B). 
3.4 Associations of glycans with type 2 diabetes 
Multiple glycan traits were associated with type 2 diabetes in both the discovery and the 
replication cohort in all three models (Supplementary Table S5). Adding BMI as a covariate in 
model 2 affected p-values and effect sizes compared to model 1, but did not alter the direction of 
the associations and only few lost statistical significance. The replicated associations that remained 
significant after adjustment for additional risk factors in model 3 are shown in Table 2. The 
strongest associations were found for sialylated traits, particularly for di- and triantennary glycans 
(Figure 3). Sialylation of diantennary traits was higher in individuals with type 2 diabetes than in 
controls. Regarding sialic-acid linkage, diantennary α2,6-linked sialylation was increased and 
triantennary α2,3-linked sialylation was decreased in diabetes (A2(F)GE and A3L). In addition to 
sialylation changes, decreased bisection of mainly fucosylated sialylated diantennary species, and 
fucosylation of diantennary traits were associated with type 2 diabetes (A2FSB and A2F). 
Moreover, the total abundance of fucosylated nonsialylated diantennary species (TA2FS0), most 
likely derived from IgG [33], was decreased (Figure 3; Table 2). 
Several derived traits that were associated with type 2 diabetes in the discovery cohort 
throughout the three models, also showed associations in the same direction in the smaller 
replication cohort, but lost significance after adjustment for risk factors for type 2 diabetes in model 
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3 (Supplementary Table S5). For instance, the abundance of diantennary N-glycans (CA2) was 
lower in type 2 diabetes while that of triantennary N-glycans (CA3) was higher. Galactosylation 
was decreased and bisection increased in traits related to IgG (A2FS0G and A2FS0B). In contrast, 
galactosylation of sialylated diantennary glycans was increased (A2SG). Αlpha2,3-sialylation of 
tetraantennary species (A4L) was decreased in type 2 diabetes, while α2,3-sialylation of 
fucosylated diantennary glycans (A2F(G)L) was increased, although only in the models adjusted 
for BMI (models 2 and 3). 
Figure 2: Associations of selected derived 
glycans with age, sex, BMI, HDL-cholesterol 
(HDLc), non-HDLc, and smoking for combined 
data from discovery and replication subsamples. 
Associations were adjusted for age, sex, and their 
interaction. Colors represent the t-statistics (β / 
standard error); the × indicates p-values ≤ 0.033 
(significance after FDR-adjustment). See 
Supplementary Table S2 for glycan derived trait 
description. Glycan trait abbreviations: B, bisection; 
C, within complex; A2, diantennary; F, fucosylation; 
L, α2,3-linked sialylation; S, sialylation; G, 
galactose; E, α2,6-linked sialylation; A3, 
triantennary; T, within total. Negative associations 
with type 2 diabetes are shown in blue, positive 
associations in red. Ever smoked, SmokEver; 
currently smoking, SmokCurr. 
 
When assessing the contributions of 
individual glycan compositions, it becomes 
apparent that mainly the mono-, di-, and tri-α2,6-
sialylated triantennary glycans H6N5E(1-3) 
drove the increase of A3E in diabetes 
(Supplementary Table S6). Various IgG-related 
compositions, such as H4N4F1, H5N4F1, and 
H5N5F1 showed a decrease, as well as various 
α2,3-sialylated species, such as H7N6(F1)E1L3 
and H5N4(F1)E1L1.  
4 DISCUSSION 
Here, we describe associations of multiple plasma protein N-glycosylation features with 
type 2 diabetes. We found that sialylation of diantennary glycans was higher in type 2 diabetes 
than in healthy controls, while fucosylation and bisection were lower. Intriguingly, diabetes was 
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strongly associated with the type of sialic-acid linkage, with lower α2,3-linked sialylation of 
triantennary glycans and higher α2,6-linked sialylation of diantennary structures.  
 
Table 2. Associations between N-glycans and type 2 diabetes. 
 
 
Model 1: Age, sex, interaction Model 2: Age, sex, interaction, 
BMI 
Model 3: Age, sex, interaction, 
BMI, HDL-c, nonHDL-c, smoking 
  Discovery   Replication  Discovery  Replication  Discovery  Replication 
Sample number (cases/controls) 1583 / 728 232 / 108 1457 / 711 232 / 106 1308 / 650 206 / 100 
Trait Description OR p OR p OR p OR P OR p OR p 
Bisection (B)             
CB in complex  0.82 2.17E-05 0.62 1.10E-04 0.86 3.37E-03 0.61 4.14E-04 0.86 1.45E-02 0.53 1.42E-03 
A2B in diantennary (A2) 0.85 3.02E-04 0.64 2.69E-04 0.87 9.80E-03 0.61 4.73E-04 0.87 2.84E-02 0.54 1.53E-03 
A2FSB in fucosylated sialylated A2 0.83 9.19E-05 0.68 1.71E-03 0.87 1.12E-02 0.67 5.53E-03 0.83 5.94E-03 0.61 1.05E-02 
Fucosylation (F)             
CF in complex 0.77 2.45E-08 0.62 1.21E-04 0.78 6.10E-06 0.60 3.61E-04 0.80 8.46E-04 0.61 9.05E-03 
A2F in diantennary (A2) 0.77 1.17E-08 0.61 6.53E-05 0.79 8.24E-06 0.59 2.33E-04 0.81 1.26E-03 0.61 1.14E-02 
A2L0F in A2 w/o α2,3-sialylation 0.77 1.49E-08 0.61 6.77E-05 0.79 4.75E-06 0.59 2.74E-04 0.80 5.54E-04 0.61 1.17E-02 
Sialylation (S)             
CS in complex 1.47 2.83E-16 1.72 1.20E-05 1.38 8.78E-10 1.54 2.10E-03 1.46 7.65E-09 1.65 8.26E-03 
A2S in diantennary (A2) 1.50 3.31E-18 1.95 2.68E-07 1.38 7.83E-10 1.80 8.54E-05 1.38 9.92E-07 1.87 1.78E-03 
A2GS per galactose in A2 1.57 2.48E-21 2.18 6.83E-09 1.40 2.66E-10 1.98 1.15E-05 1.34 7.99E-06 1.90 1.30E-03 
A2FS in fucosylated A2 1.61 9.72E-23 1.89 1.32E-06 1.46 9.88E-12 1.59 1.80E-03 1.55 4.09E-10 1.75 4.19E-03 
A2FGS per galactose in fucosylated A2 1.84 5.72E-33 2.35 1.31E-09 1.58 7.58E-16 1.94 3.4E-05 1.60 2.91E-11 1.93 9.69E-04 
α2,6-sialylation (E)             
A2E in diantennary (A2) 1.66 4.74E-26 2.15 1.53E-08 1.44 2.04E-11 1.84 7.96E-05 1.40 5.48E-07 1.96 1.18E-03 
A2GE per galactose in A2 1.76 7.36E-31 2.45 3.26E-10 1.45 6.32E-12 2.01 1.62E-05 1.36 4.91E-06 2.02 8.21E-04 
A2FE in fucosylated A2 1.63 4.82E-23 1.77 1.19E-05 1.38 7.84E-09 1.36 3.48E-02 1.45 1.51E-07 1.64 1.15E-02 
A2FGE per galactose in fucosylated A2 1.79 5.01E-30 2.09 6.37E-08 1.44 2.26E-10 1.53 5.20E-03 1.44 3.52E-07 1.79 4.26E-03 
α2,3-sialylation (L)             
A3L in triantennary (A3) 0.45 1.32E-47 0.33 2.42E-11 0.58 1.36E-18 0.50 1.42E-04 0.60 6.38E-11 0.54 1.08E-02 
A3FL in fucosylated A3 0.55 7.45E-29 0.42 4.76E-08 0.69 3.35E-10 0.60 2.85E-03 0.69 1.02E-06 0.53 5.68E-03 
IgG-related             
TA2FS0 fucosylated nonsialylated A2 in total 0.69 5.90E-15 0.59 1.69E-05 0.74 8.07E-09 0.65 1.73E-03 0.70 1.13E-08 0.59 5.68E-03 
 
Associations of N-glycans with type 2 diabetes were assessed with logistic regression, and the Benjamini-Hochberg 
procedure was applied to control for multiple testing (cut-off at 5% false discovery rate). Glycan trait abbreviations 
are as follows: B, bisection; C, within complex; A2, diantennary; F, fucosylation; L, α2,3-linked sialylation; S, 
sialylation; G, galactose; E, α2,6-linked sialylation; A3, triantennary; T, within total. Negative associations with type 
2 diabetes are shown in blue, positive associations in red. BMI, body mass index; HDL-c, HDL-cholesterol; OR, 
odds ratio; p, p-value. 
 
Type 2 diabetes is a complex and multifactorial disease, characterized by metabolic 
disturbances often accompanied by obesity and low-grade systemic inflammation [34]. 
Considering the large disease burden of type 2 diabetes, a deeper insight into its pathophysiology 
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is crucial. Studying protein N-glycosylation as a common posttranslational modification with high 
complexity, diversity, and functional impact has high potential for advancing this knowledge. 
Associations of unspecific serum/plasma glycan markers, i.e. total levels of sialic acid and N-
acetylhexosamine, with inflammation and incident type 2 diabetes have previously been described 
and are partly explained by an absolute increase in acute phase proteins [23, 24, 35]. Our 
exploration of relative shifts of N-glycan patterns may point at pathophysiological processes 
involving multiple proteins, as we discuss below.   
4.1 Sialylation 
We observed increased sialylation of fucosylated diantennary structures in type 2 diabetes 
patients, which has previously been reported for individuals at risk of developing diabetes as well 
as in acute (post-surgical) inflammation [11, 25, 36]. Sialic acids influence plasma protein 
clearance and are directly involved in activation and control of the immune system. Moreover, 
their functions depend on the linkage type [22, 37]. Our finding of increased sialylation in diabetes 
and with increasing BMI was specifically due to α2,6-sialylation, while α2,3-sialylation decreased. 
Beta-galactoside alpha-2,6-sialyltransferase-1 (ST6Gal1), encoded by the ST6GAL1 gene, is the 
enzyme attaching α2,6-sialic acid to N-glycans [38]. Interestingly, polymorphisms of ST6GAL1 
have been associated with type 2 diabetes in South East Asians [39], suggesting a potential causal 
relation between α2,6-sialylation and type 2 diabetes. ST6Gal1 enzyme activity was increased 
upon inflammation in both serum and liver in rats [40]. Moreover, an inflammation-limiting role 
of ST6Gal1 in plasma has been proposed in a study on aging [38]. It is tempting to speculate that 
increased ST6Gal1 enzyme activity may be a response to the low-grade chronic inflammation in 
type 2 diabetes. 
The majority of the α2,6-sialylated diantennary fucosylated glycans (A2FGE) and the 
triantennary mono-α2,6-sialylated glycan H6N5E1, which were positively associated with type 2 
diabetes in our study, are thought to be derived from soluble IgM and haptoglobin, respectively 
[33, 41, 42]. IgM and haptoglobin function as ligands for siglec-2 (CD22) [43], a sialic-acid-
binding Ig-like lectin present on immune cells and pancreatic β-cells [44]. Increased α2,6-linked 
sialylation of IgM and haptoglobin might augment binding to CD22, and may thus have a role in 
inflammation and possibly also glucose homeostasis.  
In contrast to α2,6-linked sialylation, α2,3-linked sialylation of larger glycans was lower 
in type 2 diabetes. The opposite was found in post-surgical, acute inflammation, where highly 
sialylated tri- and tetraantennary fucosylated glycans increased [11, 36]. Moreover, both α2,3- and 
α2,6-linked sialylation of larger glycans were higher in inflammatory bowel disease patients 
compared to healthy controls [45]. Large, sialylated, fucosylated glycans often contain terminal 
sialyl-Lewis X epitopes (consisting of an antennary fucose with an α2,3-linked sialic acid), 
especially on acute-phase proteins [33, 35, 46]. Increased abundance of sialyl-Lewis X epitopes 
on plasma glycoproteins during inflammation has been postulated to exert anti-inflammatory 
effects through competitive binding to endothelial E-selectin and blocking of immune-cell 
adhesion and extravasation into tissues [47]. Thus, reduced α2,3-linked sialylation in type 2 
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diabetes might be a sign of either disrupted anti-inflammatory mechanisms or other processes 
specific to type 2 diabetes that are not related to inflammation. Since data on sialylation in disease 
states is scarce, it remains unclear whether reduced α2,3-linked sialylation is only seen in diabetes 
or also in other diseases. 
 
 
Figure 3: Selected derived glycan traits in healthy controls (HC, green) and individuals with type 2 
diabetes (T2D, red) from the discovery cohort. The 25th, 50th and 75th percentiles and whiskers at 1st 
quartile minus 1.5*interquartile range (Q1 - 1.5*IQR) and Q3 + 1.5*IQR of the relative intensities are 
shown. P-values are shown for significant, replicated associations after adjustment for age, sex, and their 
interaction (model 1). See Table 2 for the entire list of replicated associations and Supplementary Table 
S2 for details on the derived glycan traits. A2, diantennary; F, fucosylation; G, galactosylation; S, 
sialylation; E, α2,6-linked sialylation; A3, triantennary; L, α2,3-linked sialylation; T, in total spectrum; B, 
bisection. 
4.2 Fucosylation 
We observed a decrease in fucosylation of diantennary glycans (A2F) in type 2 diabetes, 
which has also been linked to inflammation [36], increased C-reactive protein levels, and smoking 
[15]. This decrease was driven by decreases of the fucosylated species H4N4F1(E1), H5N4F1(E1), 
H5N5F1, H3N4F1, and H4N5F1. In healthy individuals, these glycans are mostly derived from 
IgG, and partly from other Igs [33, 48]. Thus, the decreased fucosylation of diantennary glycans 
might reflect a relative decrease of IgG glycans. Accordingly, decreased absolute IgG levels have 
been reported in type 2 diabetes [49]. Moreover, we recently found decreased fucosylation of 
nonsialylated, non-bisected IgG glycans in type 2 diabetes [19], which enhances the antibody-
dependent cytotoxicity of IgG [50]. In contrast, Itoh et al. found an increased relative amount of 
the core-fucosylated bisected diantennary glycan (H5N5F1) in sera of individuals with type 2 
diabetes [51]. However, a low-resolution analytical technique was used, bearing the risk of an 
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overlap of different structures, and results were not adjusted for age, sex and risk factors for 
diabetes. 
Our MS-based glycomics technique does not reveal whether a fucose is attached to an 
antennary N-acetylglucosamine or to the core. However, chromatographic analyses indicate that 
diantennary glycans mostly carry core-fucoses, while tri- and tetraantennary structures are more 
likely to carry antennary fucoses [12, 36]. Fucosylation co-occurring with an α2,3-linked sialic 
acid could indicate an antennary fucose within a sialyl-Lewis X epitope, as discussed in the 
sialylation paragraph. As an approximation of antennary fucosylation, we used glycans bearing 
two fucoses, which are represented by traits A3Fa and A4Fa and imply the presence of at least one 
antennary fucose. These were positively associated with age, BMI and smoking, but not with 
diabetes. Accordingly, in a previous report, no differences were found in the proportion of 
antennary fucosylated triantennary glycans between type 2 diabetes and healthy controls. In 
contrast, individuals with MODY3 showed decreased antennary fucosylation of triantennary 
glycans compared to both healthy and type 2 diabetes individuals [5]. MODY3 is caused by 
mutations in the HNF1A gene, which is thought to regulate fucosyltransferase activity and to 
modulate antennary fucosylation [12]. Since we found no change in antennary fucosylation in type 
2 diabetes, the decreased fucosylation is more likely caused by decreased diantennary core-
fucosylated (Ig-derived) glycans. 
4.3 Bisection 
The addition of an N-acetylglucosamine in β1,4-linkage to the first mannose of the N-
glycan core by N-acetylglucosamine-transferase-3 is called bisection. This process is in 
competition with other glycosyltransferases, including fucosyltransferase-8 for core-fucosylation 
and N-acetylglucosamine-transferase-5 for branching [52]. Bisection of fucosylated sialylated 
diantennary glycans (A2FSB) was reduced in type 2 diabetes in our cohort, while IgG-related 
bisection in the non-sialylated variant (A2FS0B) tended to increase, in agreement with our 
previous findings in isolated IgG [19]. Also, in an independent large cohort of mostly healthy 
individuals, the A2FSB trait showed a positive trend (p = 0.017) with increasing glucose-to-insulin 
ratio [15], indicative of a higher insulin sensitivity and supporting our finding in diabetes. 
Interestingly, A2FSB showed a positive association with rheumatoid arthritis, which is 
characterized by chronic inflammation [53]. In IgG, bisection enhances antibody-dependent 
cytotoxicity [50]. The biological effects of bisection in IgA and IgM glycans are largely unknown. 
A2FSB N-glycans are mostly derived from IgA, IgM, and the fragment antigen-binding portion of 
IgG, while non-bisected A2FS are mostly attributable to a mixture of glycoproteins released by 
the liver (i.e. acute phase proteins) [33]. Therefore, the decreased A2FSB possibly also reflects a 
decrease in N-glycans derived from Igs. 
4.4 Galactosylation 
Various galactosylation traits in diantennary glycans (A2G) were positively associated with 
type 2 diabetes in the first 2 models, but lost statistical significance in the replication cohort after 
adjustment for risk factors for type 2 diabetes. The latter might be due either to a power issue in 
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the smaller replication cohort or to a causal relationship of the risk factors with A2G. Very recently, 
increased galactosylation was associated with an increased risk of type 2 diabetes (age- and sex-
adjusted), in line with our findings in model 1 and 2 [25]. Beta-1,4-galactosyltransferases are 
responsible for galactosylation, and their activity in plasma has been associated with aging and 
diabetes [38, 54]. In contrast, IgG-related galactosylation (A2FS0G) tended to decrease in 
diabetes, which is in line with our study on IgG [19]. While a decrease in IgG galactosylation is a 
well-described phenomenon in different types of inflammation and aging [55], it remains unclear 
which mechanisms contribute to an increase of galactosylation in non-IgG plasma N-glycans. 
4.5 Glycan complexity 
We observed a positive association of triantennary (CA3) and a negative association of diantennary 
glycans (CA2) with type 2 diabetes in all models, although only replicated for model 1. Similarly, 
increased branching was associated with type 2 diabetes risk after adjustment for age and sex [25]. 
However, the decreased association strength after correction for BMI and other risk factors in our 
study suggests that higher glycan complexity is mediated through these risk factors.  
Lastly, the decreased ratio of high-mannose to hybrid glycans (MHy) in type 2 diabetes in 
models 1 and 2 could be due to decreased apolipoprotein B-100 levels in cases, since high-mannose 
plasma glycans are, for a large part, derived from this apolipoprotein [33]. This is reflected by the 
lower non-HDL-c in cases than controls, explained by the use of lipid-lowering treatment. 
Accordingly, after adjustment for lipids in model 3 this association lost significance in both 
cohorts. 
4.6 Strengths and limitations 
A major advantage of this study is that we were able to reliably identify and quantify 70 
different plasma N-glycan structures in a large type 2 diabetes case-control study, while others 
have focused on fewer structures with low-resolution techniques in smaller sample sizes. Our 
approach with sialic-acid derivatization provided unique insights into sialic-acid linkage-specific 
changes. The size of our discovery cohort ensured establishing robust associations between 
glycans and type 2 diabetes, even after adjustment for multiple risk factors for type 2 diabetes.  
 Nonetheless, several limitations apply to our findings. First, the glycan species analyzed 
often represent isomer mixtures, except for sialic-acid linkage isomers. Second, our data are 
normalized to the total area of the 70 detected structures and, for this reason, are dependent on the 
plasma levels of the respective glycoproteins. Future glycomic investigations on a protein-specific 
level, as previously studied in the DiaGene study for IgG [19], combined with data on the plasma 
levels of these proteins will give a deeper insight into the mechanisms underlying our observations. 
Currently, however, this is still beyond technical capabilities for large-scale studies. Third, a 
separate similar cohort was not available to replicate our findings. Instead, we created a randomly 
selected, age- and sex-matched subcohort for replication, which was smaller and therefore some 
true associations may not have become significant in this cohort. Fourth, our data is cross-sectional 
and therefore does not allow conclusions on the causality of the associations, although recent 
findings in individuals at risk of type 2 diabetes [25] are supportive of our results and do point in 
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the direction of a causal relationship. Our results are a starting point for future research in 
independent prospective cohorts. Last, we were not able to adjust for possible effects of diabetes 
treatment on N-glycan profiles due to the absolute association of the endpoint (diabetes) with the 
treatment. Collaborations are ongoing to assess treatment effects in the future. 
 
5 CONCLUSIONS 
In this cross-sectional study, we found robust associations between type 2 diabetes and the 
plasma N-glycome, especially regarding sialic-acid linkages. In part, glycans in type 2 diabetes 
appear to reflect a pro-inflammatory state. However, not all associations seem to be explained by 
inflammation, such as the observed decrease in α2,3-linked sialylation. Further studies should 
focus on protein-specific glycosylation changes. Moreover, prospective and genetic studies 
including Mendelian randomization and expression levels of glycosyltransferases and 
glycosidases should shed light on the causality and mechanisms involved. Eventually, knowledge 
on altered N-glycosylation, an essential but understudied physiological process, has the potential 
to improve insight in the pathophysiology of type 2 diabetes and could contribute to decreasing 
the burden of this major disease. 
 
6 ACKNOWLEDGEMENTS 
We are grateful to Carolien AM Koeleman for her technical support during the glycomics 
measurements. 
7 DATA STATEMENT 
Mass spectrometric data of the standard samples is available on Mendeley Data, under 
https://data.mendeley.com/datasets/zt3xb42ngz/2; DOI: 10.17632/zt3xb42ngz.2. Other data are 
available from the corresponding author upon reasonable request. 
8 FUNDING  
This study was funded by the individual Erasmus MC Fellowship Grant of Mandy van 
Hoek (glycan analysis) and by the European Union FP7 grant “HighGlycan” under grant 
agreement HEALTH-F5-2011-278535 (K.R.R., A.L.H.E. and M.W.). The funding sources were 
not involved in in study design; in the collection, analysis and interpretation of data, the writing of 
the report, or the decision to submit the article for publication. 
The data that support the findings of this study are available from the corresponding author 
upon reasonable request. 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   17 
Elsevier B.V. All rights reserved 
9 DECLARATION OF INTEREST 
K.R.R. and M.W. are inventors on a patent application on sialic acid derivatization by ethyl 
esterification. V.D., R.L, M.v.H, M.T.M, E.J.G.S, A.G.L., and A.L.H.E. declare no conflicts of 
interest.  
 
10 CONTRIBUTION STATEMENT 
E.J.G.S. and M.v.H. conceived the clinical study; E.J.G.S, M.v.H., A.G.L., M.T.M., and 
R.F.H.L. conducted the clinical study and maintained the clinical files and database. M.W. 
conceived the glycomic experiments; A.L.H.E. conducted glycomic analysis; A.L.H.E. and V.D. 
processed glycomic raw data; R.F.H.L. conducted the experiments on non-glycomic analyses. 
V.D., R.F.H.L., K.R.R., E.J.G.S., M.W. and M.v.H. developed the strategy for statistical analysis. 
K.R.R. developed the R-scripts for data analysis. V.D. and R.F.H.L. analysed data and wrote the 
manuscript. M.W., K.R.R., E.J.G.S. and M.v.H. edited the manuscript. All authors reviewed the 
manuscript and have given approval to the final version of the manuscript. 
11 REFERENCES 
[1] WHO, Global report on diabetes, World Health Organization, 2016. 
[2] P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen, Multifactorial intervention and 
cardiovascular disease in patients with type 2 diabetes, The New England journal of medicine, 348 (2003) 
383-393. 
[3] C.J. Nolan, P. Damm, M. Prentki, Type 2 diabetes across generations: from pathophysiology to 
prevention and management, The Lancet, 378 (2011) 169-181. 
[4] G. Lauc, M. Pezer, I. Rudan, H. Campbell, Mechanisms of disease: The human N-glycome, Biochim. 
Biophys. Acta, Gen. Subj. , 1860 (2016) 1574-1582. 
[5] G. Thanabalasingham, J.E. Huffman, J.J. Kattla, M. Novokmet, I. Rudan, A.L. Gloyn, C. Hayward, B. 
Adamczyk, R.M. Reynolds, A. Muzinic, N. Hassanali, M. Pucic, A.J. Bennett, A. Essafi, O. Polasek, S.A. 
Mughal, I. Redzic, D. Primorac, L. Zgaga, I. Kolcic, T. Hansen, D. Gasperikova, E. Tjora, M.W.J. Strachan, 
T. Nielsen, J. Stanik, I. Klimes, O.B. Pedersen, P.R. Njølstad, S.H. Wild, U. Gyllensten, O. Gornik, J.F. 
Wilson, N.D. Hastie, H. Campbell, M.I. McCarthy, P.M. Rudd, K.R. Owen, G. Lauc, A.F. Wright, 
Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile, Diabetes, 62 (2013) 1329. 
[6] A.G. McDonald, J.M. Hayes, G.P. Davey, Metabolic flux control in glycosylation, Current opinion in 
structural biology, 40 (2016) 97-103. 
[7] M.I. McCarthy, Painting a new picture of personalised medicine for diabetes, Diabetologia, 60 (2017) 
793-799. 
[8] A. Varki, Biological roles of glycans, Glycobiology, 27 (2017) 3-49. 
[9] S. Ahmad, M.S. Khan, F. Akhter, M.S. Khan, A. Khan, J.M. Ashraf, R.P. Pandey, U. Shahab, 
Glycoxidation of Biological Macromolecules: A Critical Approach to Halt the Menace of Glycation, 
Glycobiology, 24 (2014) 979-990. 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   18 
Elsevier B.V. All rights reserved 
[10] R. Hennig, S. Cajic, M. Borowiak, M. Hoffmann, R. Kottler, U. Reichl, E. Rapp, Towards personalized 
diagnostics via longitudinal study of the human plasma N-glycome, Biochimica et biophysica acta, 1860 
(2016) 1728-1738. 
[11] M. Novokmet, E. Lukić, F. Vučković, Ž. –Durić, T. Keser, K. Rajšl, D. Remondini, G. Castellani, H. 
Gašparović, O. Gornik, G. Lauc, Changes in IgG and total plasma protein glycomes in acute systemic 
inflammation, Scientific Reports, 4 (2014) 4347. 
[12] A. Knežević, O. Gornik, O. Polašek, M. Pučić, I. Redžić, M. Novokmet, P.M. Rudd, A.F. Wright, H. 
Campbell, I. Rudan, G. Lauc, Effects of aging, body mass index, plasma lipid profiles, and smoking on 
human plasma N-glycans, Glycobiology, 20 (2010) 959-969. 
[13] J. Krištić, F. Vučković, C. Menni, L. Klarić, T. Keser, I. Beceheli, M. Pučić-Baković, M. Novokmet, 
M. Mangino, K. Thaqi, P. Rudan, N. Novokmet, J. Šarac, S. Missoni, I. Kolčić, O. Polašek, I. Rudan, H. 
Campbell, C. Hayward, Y. Aulchenko, A. Valdes, J.F. Wilson, O. Gornik, D. Primorac, V. Zoldoš, T. 
Spector, G. Lauc, Glycans Are a Novel Biomarker of Chronological and Biological Ages, The Journals of 
Gerontology: Series A, 69 (2014) 779-789. 
[14] L.R. Ruhaak, H.W. Uh, M. Beekman, C.H. Hokke, R.G. Westendorp, J. Houwing-Duistermaat, M. 
Wuhrer, A.M. Deelder, P.E. Slagboom, Plasma protein N-glycan profiles are associated with calendar age, 
familial longevity and health, Journal of proteome research, 10 (2011) 1667-1674. 
[15] K.R. Reiding, L.R. Ruhaak, H.-W. Uh, S. el Bouhaddani, E.B. van den Akker, R. Plomp, L.A. 
McDonnell, J.J. Houwing-Duistermaat, P.E. Slagboom, M. Beekman, M. Wuhrer, Human Plasma N-
glycosylation as Analyzed by Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion 
Cyclotron Resonance-MS Associates with Markers of Inflammation and Metabolic Health, Mol. Cell. 
Proteomics 16 (2017) 228-242. 
[16] G. Lauc, A. Essafi, J.E. Huffman, C. Hayward, A. Knežević, J.J. Kattla, O. Polašek, O. Gornik, V. 
Vitart, J.L. Abrahams, M. Pučić, M. Novokmet, I. Redžić, S. Campbell, S.H. Wild, F. Borovečki, W. Wang, 
I. Kolčić, L. Zgaga, U. Gyllensten, J.F. Wilson, A.F. Wright, N.D. Hastie, H. Campbell, P.M. Rudd, I. 
Rudan, Genomics Meets Glycomics—The First GWAS Study of Human N-Glycome Identifies HNF1α as 
a Master Regulator of Plasma Protein Fucosylation, PLOS Genetics, 6 (2010) e1001256. 
[17] T.J. McDonald, S. Ellard, Maturity onset diabetes of the young: identification and diagnosis, Ann. 
Clin. Biochem., 50 (2013) 403-415. 
[18] B.F. Voight, L.J. Scott, V. Steinthorsdottir, A.P. Morris, C. Dina, R.P. Welch, E. Zeggini, C. Huth, 
Y.S. Aulchenko, G. Thorleifsson, L.J. McCulloch, T. Ferreira, H. Grallert, N. Amin, G. Wu, C.J. Willer, S. 
Raychaudhuri, S.A. McCarroll, C. Langenberg, O.M. Hofmann, J. Dupuis, L. Qi, A.V. Segre, M. van Hoek, 
P. Navarro, K. Ardlie, B. Balkau, R. Benediktsson, A.J. Bennett, R. Blagieva, E. Boerwinkle, L.L. 
Bonnycastle, K.B. Bostrom, B. Bravenboer, S. Bumpstead, N.P. Burtt, G. Charpentier, P.S. Chines, M. 
Cornelis, D.J. Couper, G. Crawford, A.S.F. Doney, K.S. Elliott, A.L. Elliott, M.R. Erdos, C.S. Fox, C.S. 
Franklin, M. Ganser, C. Gieger, N. Grarup, T. Green, S. Griffin, C.J. Groves, C. Guiducci, S. Hadjadj, N. 
Hassanali, C. Herder, B. Isomaa, A.U. Jackson, P.R.V. Johnson, T. Jorgensen, W.H.L. Kao, N. Klopp, A. 
Kong, P. Kraft, J. Kuusisto, T. Lauritzen, M. Li, A. Lieverse, C.M. Lindgren, V. Lyssenko, M. Marre, T. 
Meitinger, K. Midthjell, M.A. Morken, N. Narisu, P. Nilsson, K.R. Owen, F. Payne, J.R.B. Perry, A.-K. 
Petersen, C. Platou, C. Proenca, I. Prokopenko, W. Rathmann, N.W. Rayner, N.R. Robertson, G. 
Rocheleau, M. Roden, M.J. Sampson, R. Saxena, B.M. Shields, P. Shrader, G. Sigurdsson, T. Sparso, K. 
Strassburger, H.M. Stringham, Q. Sun, A.J. Swift, B. Thorand, J. Tichet, T. Tuomi, R.M. van Dam, T.W. 
van Haeften, T. van Herpt, J.V. van Vliet-Ostaptchouk, G.B. Walters, M.N. Weedon, C. Wijmenga, J. 
Witteman, R.N. Bergman, S. Cauchi, F.S. Collins, A.L. Gloyn, U. Gyllensten, T. Hansen, W.A. Hide, G.A. 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   19 
Elsevier B.V. All rights reserved 
Hitman, A. Hofman, D.J. Hunter, K. Hveem, M. Laakso, K.L. Mohlke, A.D. Morris, C.N.A. Palmer, P.P. 
Pramstaller, I. Rudan, E. Sijbrands, L.D. Stein, J. Tuomilehto, A. Uitterlinden, M. Walker, N.J. Wareham, 
R.M. Watanabe, G.R. Abecasis, B.O. Boehm, H. Campbell, M.J. Daly, A.T. Hattersley, F.B. Hu, J.B. 
Meigs, J.S. Pankow, O. Pedersen, H.E. Wichmann, I. Barroso, J.C. Florez, T.M. Frayling, L. Groop, R. 
Sladek, U. Thorsteinsdottir, J.F. Wilson, T. Illig, P. Froguel, C.M. van Duijn, K. Stefansson, D. Altshuler, 
M. Boehnke, M.I. McCarthy, Twelve type 2 diabetes susceptibility loci identified through large-scale 
association analysis, Nat. Genet., 42 (2010) 579-589. 
[19] R.F.H. Lemmers, M. Vilaj, D. Urda, F. Agakov, M. Šimurina, L. Klaric, I. Rudan, H. Campbell, C. 
Hayward, J.F. Wilson, A.G. Lieverse, O. Gornik, E.J.G. Sijbrands, G. Lauc, M. van Hoek, IgG glycan 
patterns are associated with type 2 diabetes in independent European populations, Biochim. Biophys. Acta, 
Gen. Subj. , 1861 (2017) 2240-2249. 
[20] K. Tanigaki, A. Sacharidou, J. Peng, K.L. Chambliss, I.S. Yuhanna, D. Ghosh, M. Ahmed, A.J. Szalai, 
W. Vongpatanasin, R.F. Mattrey, Q. Chen, P. Azadi, I. Lingvay, M. Botto, W.L. Holland, J.J. Kohler, S.R. 
Sirsi, K. Hoyt, P.W. Shaul, C. Mineo, Hyposialylated IgG activates endothelial IgG receptor FcgammaRIIB 
to promote obesity-induced insulin resistance, The Journal of clinical investigation, 10.1172/jci89333 
(2017). 
[21] R. Testa, V. Vanhooren, A.R. Bonfigli, M. Boemi, F. Olivieri, A. Ceriello, S. Genovese, L. 
Spazzafumo, V. Borelli, M.G. Bacalini, S. Salvioli, P. Garagnani, S. Dewaele, C. Libert, C. Franceschi, N-
Glycomic Changes in Serum Proteins in Type 2 Diabetes Mellitus Correlate with Complications and with 
Metabolic Syndrome Parameters, PLOS ONE, 10 (2015) e0119983. 
[22] A. Varki, P. Gagneux, Multifarious roles of sialic acids in immunity, Ann. N. Y. Acad. Sci., 1253 
(2012) 16-36. 
[23] M.I. Schmidt, B.B. Duncan, A.R. Sharrett, G. Lindberg, P.J. Savage, S. Offenbacher, M.I. Azambuja, 
R.P. Tracy, G. Heiss, Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis 
Risk in Communities study): a cohort study, The Lancet, 353 (1999) 1649-1652. 
[24] A.O. Akinkuolie, A.D. Pradhan, J.E. Buring, P.M. Ridker, S. Mora, Novel Protein Glycan Side-Chain 
Biomarker and Risk of Incident Type 2 Diabetes Mellitus, Arterioscler., Thromb., Vasc. Biol. , 35 (2015) 
1544. 
[25] T. Keser, I. Gornik, F. Vuckovic, N. Selak, T. Pavic, E. Lukic, I. Gudelj, H. Gasparovic, B. Biocina, 
T. Tilin, A. Wennerstrom, S. Mannisto, V. Salomaa, A. Havulinna, W. Wang, J.F. Wilson, N. Charutvedi, 
M. Perola, H. Campbell, G. Lauc, O. Gornik, Increased plasma N-glycome complexity is associated with 
higher risk of type 2 diabetes, Diabetologia, 10.1007/s00125-017-4426-9 (2017). 
[26] K.R. Reiding, D. Blank, D.M. Kuijper, A.M. Deelder, M. Wuhrer, High-throughput profiling of protein 
N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification, Analytical 
chemistry, 86 (2014) 5784-5793. 
[27] T.T.W. van Herpt, R.F.H. Lemmers, M. van Hoek, J.G. Langendonk, R.J. Erdtsieck, B. Bravenboer, 
A. Lucas, M.T. Mulder, H.R. Haak, A.G. Lieverse, E.J.G. Sijbrands, Introduction of the DiaGene study: 
clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes, 
Diabetol. Metab. Syndr., 9 (2017) 47. 
[28] M.R. Bladergroen, K.R. Reiding, A.L. Hipgrave Ederveen, G.C. Vreeker, F. Clerc, S. Holst, A. Bondt, 
M. Wuhrer, Y.E. van der Burgt, Automation of High-Throughput Mass Spectrometry-Based Plasma N-
Glycome Analysis with Linkage-Specific Sialic Acid Esterification, Journal of proteome research, 14 
(2015) 4080-4086. 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   20 
Elsevier B.V. All rights reserved 
[29] B.C. Jansen, K.R. Reiding, A. Bondt, A.L. Hipgrave Ederveen, M. Palmblad, D. Falck, M. Wuhrer, 
MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality 
Control Developed for Glycomic and Glycoproteomic MALDI-MS, Journal of proteome research, 14 
(2015) 5088-5098. 
[30] F. Clerc, K.R. Reiding, B.C. Jansen, G.S.M. Kammeijer, A. Bondt, M. Wuhrer, Human plasma protein 
N-glycosylation, Glycoconjugate Journal, 33 (2016) 309-343. 
[31] F. Faul, E. Erdfelder, A. Buchner, A.G. Lang, Statistical power analyses using G*Power 3.1: tests for 
correlation and regression analyses, Behavior research methods, 41 (2009) 1149-1160. 
[32] Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach 
to Multiple Testing, Journal of the Royal Statistical Society. Series B (Methodological), 57 (1995) 289-
300. 
[33] F. Clerc, K.R. Reiding, B.C. Jansen, G.S.M. Kammeijer, A. Bondt, M. Wuhrer, Human plasma protein 
N-glycosylation, Glycoconjugate J. , 33 (2016) 309-343. 
[34] G.S. Hotamisligil, Inflammation, metaflammation and immunometabolic disorders, Nature, 542 
(2017) 177-185. 
[35] C. McCarthy, R. Saldova, M.R. Wormald, P.M. Rudd, N.G. McElvaney, E.P. Reeves, The Role and 
Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and 
Chronic Inflammatory Conditions, Journal of proteome research, 13 (2014) 3131-3143. 
[36] I. Gudelj, M. Baciarello, I. Ugrina, M. De Gregori, V. Napolioni, P.M. Ingelmo, D. Bugada, S. De 
Gregori, L. Đerek, M. Pučić-Baković, M. Novokmet, O. Gornik, G. Saccani Jotti, T. Meschi, G. Lauc, M. 
Allegri, Changes in total plasma and serum N-glycome composition and patient-controlled analgesia after 
major abdominal surgery, Scientific Reports, 6 (2016) 31234. 
[37] T.R. McCurdy, V. Bhakta, L.J. Eltringham-Smith, S. Gataiance, A.E. Fox-Robichaud, W.P. Sheffield, 
In Vivo Clearance of Alpha-1 Acid Glycoprotein Is Influenced by the Extent of Its N-Linked Glycosylation 
and by Its Interaction with the Vessel Wall, J. Biomed. Biotechnol., 2012 (2012) 11. 
[38] M. Catera, V. Borelli, N. Malagolini, M. Chiricolo, G. Venturi, C.A. Reis, H. Osorio, P.M. Abruzzo, 
M. Capri, D. Monti, R. Ostan, C. Franceschi, F. Dall'Olio, Identification of novel plasma glycosylation-
associated markers of aging, Oncotarget, 7 (2016) 7455-7468. 
[39] J.S. Kooner, D. Saleheen, X. Sim, J. Sehmi, W. Zhang, P. Frossard, L.F. Been, K.-S. Chia, A.S. Dimas, 
N. Hassanali, T. Jafar, J.B.M. Jowett, X. Li, V. Radha, S.D. Rees, F. Takeuchi, R. Young, T. Aung, A. 
Basit, M. Chidambaram, D. Das, E. Grundberg, A.K. Hedman, Z.I. Hydrie, M. Islam, C.-C. Khor, S. 
Kowlessur, M.M. Kristensen, S. Liju, W.-Y. Lim, D.R. Matthews, J. Liu, A.P. Morris, A.C. Nica, J.M. 
Pinidiyapathirage, I. Prokopenko, A. Rasheed, M. Samuel, N. Shah, A.S. Shera, K.S. Small, C. Suo, A.R. 
Wickremasinghe, T.Y. Wong, M. Yang, F. Zhang, G.R. Abecasis, A.H. Barnett, M. Caulfield, P. Deloukas, 
T.M. Frayling, P. Froguel, N. Kato, P. Katulanda, M.A. Kelly, J. Liang, V. Mohan, D.K. Sanghera, J. Scott, 
M. Seielstad, P.Z. Zimmet, P. Elliott, Y.Y. Teo, M.I. McCarthy, J. Danesh, E.S. Tai, J.C. Chambers, 
Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes 
susceptibility loci, Nat. Genet., 43 (2011) 984-989. 
[40] H.A. Kaplan, B.M. Woloski, M. Hellman, J.C. Jamieson, Studies on the effect of inflammation on rat 
liver and serum sialyltransferase. Evidence that inflammation causes release of Gal beta 1 leads to 4GlcNAc 
alpha 2 leads to 6 sialyltransferase from liver, J. Biol. Chem. , 258 (1983) 11505-11509. 
[41] J.N. Arnold, M.R. Wormald, D.M. Suter, C.M. Radcliffe, D.J. Harvey, R.A. Dwek, P.M. Rudd, R.B. 
Sim, Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin, 
J. Biol. Chem. , 280 (2005) 29080-29087. 
V. Dotz et al.                                                 POSTPRINT                  
 Biochimica et Biophysica Acta - General Subjects 1862 (2018) 2613–262 
https://doi.org/10.1016/j.bbagen.2018.08.005   21 
Elsevier B.V. All rights reserved 
[42] S. Zhang, K. Jiang, C. Sun, H. Lu, Y. Liu, Quantitative analysis of site-specific N-glycans on sera 
haptoglobin beta chain in liver diseases, Acta biochimica et biophysica Sinica, 45 (2013) 1021-1029. 
[43] K. Hanasaki, L.D. Powell, A. Varki, Binding of Human Plasma Sialoglycoproteins by the B Cell-
specific Lectin CD22: SELECTIVE RECOGNITION OF IMMUNOGLOBULIN M AND 
HAPTOGLOBIN, J. Biol. Chem. , 270 (1995) 7543-7550. 
[44] G. Dharmadhikari, K. Stolz, M. Hauke, N.G. Morgan, A. Varki, E. de Koning, S. Kelm, K. Maedler, 
Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients 
with diabetes, Scientific Reports, 7 (2017) 45319. 
[45] F. Clerc, M. Novokmet, V. Dotz, K.R. Reiding, N. de Haan, G.S.M. Kammeijer, H. Dalebout, M.R. 
Bladergroen, F. Vukovic, E. Rapp, I.-B. consortium, S.R. Targan, G. Barron, N. Manetti, A. Latiano, D.P.B. 
McGovern, V. Annese, G. Lauc, M. Wuhrer, Plasma N-Glycan Signatures Associate With Features of 
Inflammatory Bowel Diseases, Gastroenterology, 10.1053/j.gastro.2018.05.030 (2018). 
[46] E.C. Brinkman-van der Linden, P.F. de Haan, E.C. Havenaar, W. van Dijk, Inflammation-induced 
expression of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent 
on alpha1-antichymotrypsin and haptoglobin, Glycoconjugate J. , 15 (1998) 177-182. 
[47] H.G. Jorgensen, M.A. Elliott, R. Priest, K.D. Smith, Modulation of sialyl Lewis X dependent binding 
to E-selectin by glycoforms of alpha-1-acid glycoprotein expressed in rheumatoid arthritis, Biomedical 
chromatography : BMC, 12 (1998) 343-349. 
[48] M. Colucci, H. Stöckmann, A. Butera, A. Masotti, A. Baldassarre, E. Giorda, S. Petrini, P.M. Rudd, 
R. Sitia, F. Emma, M. Vivarelli, Sialylation of N-Linked Glycans Influences the Immunomodulatory 
Effects of IgM on T Cells, J. Immunol., 194 (2014) 151. 
[49] X. Guo, G. Meng, F. Liu, Q. Zhang, L. Liu, H. Wu, H. Du, H. Shi, Y. Xia, X. Liu, C. Li, X. Bao, Q. 
Su, Y. Gu, L. Fang, F. Yu, H. Yang, B. Yu, S. Sun, X. Wang, M. Zhou, Q. Jia, X. Chen, G. Huang, K. 
Song, K. Niu, Serum levels of immunoglobulins in an adult population and their relationship with type 2 
diabetes, Diabetes Res. Clin. Pract., 115 (2016) 76-82. 
[50] T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. 
Anazawa, M. Satoh, M. Yamasaki, N. Hanai, K. Shitara, The absence of fucose but not the presence of 
galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the 
critical role of enhancing antibody-dependent cellular cytotoxicity, J. Biol. Chem. , 278 (2003) 3466-3473. 
[51] N. Itoh, S. Sakaue, H. Nakagawa, M. Kurogochi, H. Ohira, K. Deguchi, S.-I. Nishimura, M. Nishimura, 
Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes, Am. J. 
Physiol. Endocrinol. Metabolism, 293 (2007) E1069. 
[52] A. Kurimoto, S. Kitazume, Y. Kizuka, K. Nakajima, R. Oka, R. Fujinawa, H. Korekane, Y. 
Yamaguchi, Y. Wada, N. Taniguchi, The Absence of Core Fucose Up-regulates GnT-III and Wnt Target 
Genes: A POSSIBLE MECHANISM FOR AN ADAPTIVE RESPONSE IN TERMS OF GLYCAN 
FUNCTION, J. Biol. Chem. , 289 (2014) 11704-11714. 
[53] K.R. Reiding, G.C.M. Vreeker, A. Bondt, M.R. Bladergroen, J.M.W. Hazes, Y.E.M. van der Burgt, 
M. Wuhrer, R. Dolhain, Serum Protein N-Glycosylation Changes with Rheumatoid Arthritis Disease 
Activity during and after Pregnancy, Frontiers in medicine, 4 (2017) 241. 
[54] L.P. Lee, A. Prasad, K.J. Bolton, J.B. McKendry, I. Hynie, Serum UDP-galactose: glycoprotein 
galactosyltransferase in diabetics with microangiopathy, Clin. Biochem., 10 (1977) 111-117. 
[55] F. Dall’Olio, V. Vanhooren, C.C. Chen, P.E. Slagboom, M. Wuhrer, C. Franceschi, N-glycomic 
biomarkers of biological aging and longevity: A link with inflammaging, Ageing Res. Rev., 12 (2013) 685-
698. 
